Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyy026
Abstract: Background The combination use of the vascular disrupting agent ombrabulin with chemotherapeutic agents was previously shown to be highly synergistic in preclinical models. Methods In this dose-escalation study of ombrabulin (15.5-35 mg/m2) in combination with… read more here.
Keywords: combination; japanese patients; study ombrabulin; docetaxel cisplatin ... See more keywords